3. Pasalic, D., et al., Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials. Eur J Cancer, 2020. 136: p. 176-185. 4. World Medical Association Declaration of...
3. Pasalic, D., et al., Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials. Eur J Cancer, 2020. 136: p. 176-185. 4. World Medical Association Declaration of...
1373P Measuring PFS in clinical trials and observational studies of patients with NSCLC: A scoping reviewdoi:10.1016/j.annonc.2024.08.1428M. VerschuerenV. TassopoulouR. VisscherJ. SchuurkampB. PetersM. KoopmanE. van de GardeT. Egberts
主要分析的截止日期为2023年9月1日。http://ClinicalTrials.gov注册号:NCT03599765。 根据研究人员公布的结果:2019 年3 月至 2023 年 2 月期间,41 例胰腺导管腺癌寡转移患者随机分组后接受了治疗,其中 40 例符合 PFS 分析条件(MDT组(根治性放疗+药物治疗组):19 例患者;对照组(单独药物治疗):21 例患者)。两...
[1]https://www.clinicaltrials.gov/ct2/show/NCT03101566 [2]Vaibhav Sahai, et al. A multicenter randomized phase Ⅱ study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-01). ASCO 2020. ...
Matching-Adjusted Indirect Comparison (MAIC): Entrectinib versus Crizotinib in Asian Patients with ROS1+ NSCLC 这项MAIC研究纳入恩曲替尼试验的IPD数据和克唑替尼的AgD数据,比较两种药物治疗ROS1融合阳性NSCLC患者的疗效。恩曲替尼组患者的中位PFS为39.4个月,克唑替尼组患者的中位PFS为15.9个月(HR = 0....
[12]Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 2011;29(16):2144-9. [13]Eva María Ciruelos, María Nieves Díaz, María Dolores Isla, et al. Patient pr...
https://clinicaltrials.gov/ct2/show/NCT02367040. Dreyling M, Santoro A, Mollica L, et al. Copanlisib in patients with relapsed or refractory indolent B-cell lymphoma: primary results of the pivotal CHRONOS-1 study. Presented at: 2017 AACR Annual Meeting; April 1-5, 2017; San ...
October 5, 2020. Accessed January 2, 2025. https://tinyurl.com/32rfbjwt Study to evaluate the efficacy, safety and pharmacokinetics of CT041 autologous CAR T-cell injection. ClinicalTrials.gov. Updated March 6, 2024. Accessed January 2, 2025. https://tinyurl.com/4fm53s86...
[3] A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer...